MyVisionTest News Archive

Displaying news items tagged with Lucentis (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last

Retinal angiomatous proliferation
Nov 19, 2009
Anti-VEGF monotherapy with Lucentis or Avastin represents a useful treatment option for patients with retinal angiomatous proliferation (RAP) associated with age-related macular degeneration (AMD), according to a new study. Retinal angiomatous proliferation is a distinct form of wet AMD associated with neovascularization that originates from...

Full Article


VEGF molecule
Nov 19, 2009
Lucentis (ranibizumab) therapy for neovascular age-related macular degeneration (AMD) is associated with reduced levels of aqueous VEGF and pigment epithelium-derived factor (PEDF) regardless of combined therapy with photodynamic therapy (PDT). The reduction levels of VEGF and PEDF are correlated with anatomic improvements in the macula. A...

Full Article


Intravitreal injection
Nov 18, 2009
Vascular endothelial growth factor (VEGF) ligands and their receptors are essential for development and for a wide variety of physiologic functions through adulthood, including visual function. Given the ubiquitous physiologic role of VEGF, evaluation of potential safety risks associated with nonspecific inhibition of VEGF-A and other VEGF-related...

Full Article


Lucentis
Nov 17, 2009
Same-day verteporfin photodynamic therapy (PDT) and intravitreal Lucentis (ranibizumab) is safe and effective in the treatment of patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), according to a new study. In this open-label, prospective study patients received verteporfin PDT at...

Full Article


Intravitreal injection
Oct 26, 2009
Noninfectious endophthalmitis after anti-VEGF therapy may represent a maturing immune response to repeated doses, according to a speaker at the American Academy of Ophthalmology meeting. While infectious endophthalmitis remains a pressing concern after anti-VEGF therapy because of its potentially sight-threatening sequelae, noninfectious...

Full Article


Central retinal vein occlusion
Oct 26, 2009
Genentech, Inc. announced results from two Phase III studies of Lucentis (ranibizumab) in macular edema due to retinal vein occlusion (RVO), which showed patients given Lucentis had significant improvement in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at...

Full Article


Age-related macular degeneration
Oct 26, 2009
Lpath, Inc. reported positive results of its single-dose Phase 1 clinical trial of iSONEP, an anti-sphingosine-1-phosphate monoclonal antibody, in neovascular age-related macular degeneration (AMD) patients. iSONEP met its primary endpoint of being well tolerated in all 15 patients at dose-levels ranging from 0.2 mg. to 1.8 mg. per...

Full Article


Macular degeneration
Oct 26, 2009
Investigators have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Avastin (bevacizumab) and Lucentis (ranibizumab) for the treatment of age-related macular degeneration (AMD). The study is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial comparing...

Full Article


Pigment epithelial detachment
Oct 22, 2009
Anti-VEGF injections may be beneficial for treatment of pigment epithelium detachment secondary to neovascular age-related macular degeneration, a population that previously has not been studied in clinical trials, according to a speaker at Retina Congress 2009. In 35 patients with pigment epithelium detachment secondary to AMD, Lucentis (...

Full Article


Age-related Macular Degeneration
Oct 22, 2009
Although the optimal dosing of anti-VEGF therapy remains unknown, pharmacokinetics of the two most popular agents suggest that adjusting the current dosing strategies may better serve patient needs. Head-to-head trials of Lucentis (ranibizumab) and Avastin (bevacizumab) should help steer future treatment decisions, Philip J. Rosenfeld, MD, PhD,...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last
Most Popular
Less - past - More